Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.

Basic fibroblast growth factor (FGF-2) interacts with high-affinity tyrosine-kinase fibroblast growth factor receptors (FGFRs) and low-affinity heparan sulfate proteoglycans (HSPGs) in target cells. Both interactions are required for FGF-2-mediated biological responses. Here we report the FGF-2 antagonist activity of novel synthetic sulfonic acid polymers with distinct chemical structures and molecular masses (MMs). PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)], (MM approximately 7,000-10,000), PAS [poly(anetholesulfonic acid)], (MM approximately 9,000-11,000), PSS [poly(4-styrenesulfonic acid)], (MM = 70,000), and poly(vinylsulfonic acid) (MM = 2,000), inhibited FGF-2 binding to HSPGs and FGFRs in fetal bovine aortic endothelial GM 7373 cells. They also abrogated the formation of the HSPG/FGF-2/FGFR ternary complex, as evidenced by their capacity to prevent FGF-2-mediated cell-cell attachment of FGFR-1-overexpressing, HSPG-deficient Chinese hamster ovary cells to wild-type HSPG-bearing cells. Direct interaction of the polysulfonates with FGF-2 was demonstrated by their ability to protect the growth factor from proteolytic cleavage. Accordingly, molecular modeling, based on the crystal structure of the interaction of FGF-2 with a heparin hexamer, showed the feasibility of docking PAMPS into the heparin-binding domain of FGF-2. In agreement with their FGF-2-binding capacity, PSS, PAS, and PAMPS inhibited FGF-2-induced cell proliferation in GM 7373 cells and murine brain microvascular endothelial cells. The antiproliferative activity of these compounds was associated with the abrogation of FGF-2-induced tyrosine phosphorylation of FGFR-1. Moreover, the polysulfonates PSS and PAS inhibited FGF-2-induced activation of mitogen-activated protein kinase-1/2, involved in FGF-2 signal transduction. In conclusion, sulfonic acid polymers bind FGF-2 by mimicking heparin interaction. These compounds may provide a tool to inhibit FGF-2-induced endothelial cell proliferation in angiogenesis and tumor growth.

[1]  A. Wellstein,et al.  Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. , 1992, Journal of the National Cancer Institute.

[2]  E. De Clercq,et al.  The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. , 1997, Oncology research.

[3]  J. Turnbull,et al.  Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.

[4]  D. Moscatelli,et al.  Fibroblast Growth Factor-2 Can Mediate Cell Attachment by Linking Receptors and Heparan Sulfate Proteoglycans on Neighboring Cells (*) , 1995, The Journal of Biological Chemistry.

[5]  M. Pantoliano,et al.  Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. , 1994, Biochemistry.

[6]  D. Moscatelli,et al.  Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. , 1992, The Journal of biological chemistry.

[7]  D. Ribatti,et al.  Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. , 1995, Developmental biology.

[8]  A. Isacchi,et al.  Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. , 1993, European journal of biochemistry.

[9]  P. Dell’Era,et al.  Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. , 1994, Biochemical and biophysical research communications.

[10]  J. Esko.  Genetic analysis of proteoglycan structure, function and metabolism. , 1991, Current opinion in cell biology.

[11]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[12]  M. Pepper,et al.  Manipulating angiogenesis. From basic science to the bedside. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Y. Nagamine,et al.  Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  B. Allolio,et al.  Antiproliferative and angiostatic activity of suramin analogues. , 1995, Cancer research.

[15]  R M Esnouf,et al.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. , 1997, Journal of molecular graphics & modelling.

[16]  E A Merritt,et al.  Raster3D Version 2.0. A program for photorealistic molecular graphics. , 1994, Acta crystallographica. Section D, Biological crystallography.

[17]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[18]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Dell’Era,et al.  Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[21]  R. Florkiewicz,et al.  Multiple forms of bFGF: differential nuclear and cell surface localization. , 1991, Growth factors.

[22]  I. Lax,et al.  Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors? , 1995, Cell.

[23]  Brian W. Matthews,et al.  Refinement of the structure of human basic fibroblast growth factor at 1.6 Å resolution and analysis of presumed heparin binding sites by selenate substitution , 1993, Protein science : a publication of the Protein Society.

[24]  K. Norrby,et al.  Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. , 1996, International journal of microcirculation, clinical and experimental.

[25]  B. Olwin,et al.  Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. , 1993, The Journal of biological chemistry.

[26]  R. Nicosia,et al.  Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. , 1993, The American journal of pathology.

[27]  D. Johnson,et al.  Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.

[28]  G. Waksman,et al.  Heparin-induced Self-association of Fibroblast Growth Factor-2 , 1997, The Journal of Biological Chemistry.

[29]  P. Dell’Era,et al.  Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. , 1991, Cell regulation.

[30]  A. Sommer,et al.  Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .

[32]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[33]  M. Rusnati,et al.  Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. , 1994, The Biochemical journal.

[34]  M. Presta,et al.  Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration , 1986, Molecular and cellular biology.

[35]  L. Cousens,et al.  Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. , 1993, The Journal of biological chemistry.

[36]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[37]  D. Rifkin,et al.  Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation , 1988, The Journal of cell biology.

[38]  M. Ziche,et al.  Interaction of high‐molecular‐weight basic fibroblast growth factor with endothelium: Biological activity and intracellular fate of human recombinant Mr 24,000 bFGF , 1994, Journal of cellular physiology.

[39]  A. O. Pozdnyakov,et al.  Trapping of solvent by a C60 fullerene film , 1998 .

[40]  D C Rees,et al.  Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.

[41]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Jaye,et al.  Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation , 1994, Cell.